

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Urology

**ESPS manuscript NO:** 29404

**Title:** URINE CHEMOKINES LEVELS CORRELATE WITH TREATMENT RESPONSE TO PHOSPHODIESTERASE 4 INHIBITOR IN PROSTATITIS PATIENT

**Reviewer's code:** 00505652

### COMMENTS TO AUTHORS

The study idea seems good. I have some comments: - please remove the following sentence: "who were refractory to other therapies (e.g. NSAIDS)". How they can respond to a treatment if they are "refractory" to NSAIDS?. - please discuss among the study limitations about the very small number of enrolled patients - I suggest to remove the part of the study relating to the treatment. In this case a clinical phase I or I-II study is needed.

We thank the reviewer for the valuable comment and would like to clarify. The patients enrolled in this study were treated with a new anti-inflammatory drug called Apremilast, which works by inhibiting the enzyme phosphodiesterase 4 that metabolizes cAMP. Since the mechanism of action of Apremilast is different from NSAIDS, which work by inhibiting another enzyme called COX, the treated patients were expected to respond to Apremilast even if they were refractory to NSAIDS. It is well established paradigm that treatment refractoriness can be overcome by a drug that works by a different mechanism of action. Accordingly, we have revised the introduction to make this point clear. Additional text is highlighted in yellow. Since mechanism of action for Apremilast is different from traditional anti-inflammatory drugs (NSAIDS), it could have potential efficacy in patients refractory NSAIDS, which work by inhibiting COX instead of PDE4.

We would also like reiterate that it was a registered open label clinical trial of new anti-inflammatory drug in prostatitis patients. We have discussed the limitations of the study in the discussion section, which are highlighted in yellow.

## **ESPS PEER-REVIEW REPORT**

**Name of journal:** World Journal of Clinical Urology

**ESPS manuscript NO:** 29404

**Title:** URINE CHEMOKINES LEVELS CORRELATE WITH TREATMENT RESPONSE TO PHOSPHODIESTERASE 4 INHIBITOR IN PROSTATITIS PATIENT

**Reviewer's code:** 03387655

### **COMMENTS TO AUTHORS**

The grammar and use of english need some work, introduction is not clear, discussion is very interesting but slightly unappealing. I suggest the revision by a native english speaker.

**Response:** We thank the reviewer for the encouraging comment. The text of the manuscript is thoroughly revised to remove any errors.

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Urology

**ESPS manuscript NO:** 29404

**Title:** URINE CHEMOKINES LEVELS CORRELATE WITH TREATMENT RESPONSE TO PHOSPHODIESTERASE 4 INHIBITOR IN PROSTATITIS PATIENT

**Reviewer's code:** 03384937

| CLASSIFICATION   | LANGUAGE EVALUATION  | SCIENTIFIC MISCONDUCT                          | CONCLUSION  |
|--|--|--|---|
| <input type="checkbox"/> Grade A: Excellent            | <input checked="" type="checkbox"/> Grade A: Priority publishing     | Google Search:                                 | <input type="checkbox"/> Accept                                   |
| <input checked="" type="checkbox"/> Grade B: Very good | <input type="checkbox"/> Grade B: Minor language polishing           | <input type="checkbox"/> The same title        | <input checked="" type="checkbox"/> High priority for publication |
| <input type="checkbox"/> Grade C: Good                 |  | <input type="checkbox"/> Duplicate publication |   |
| <input type="checkbox"/> Grade D: Fair                 | <input type="checkbox"/> Grade C: A great deal of language polishing | <input type="checkbox"/> Plagiarism            | <input type="checkbox"/> Rejection                                |
| <input type="checkbox"/> Grade E: Poor                 |  | <input type="checkbox"/> No                    | <input type="checkbox"/> Minor revision                           |
|  | <input type="checkbox"/> Grade D: Rejected                           | BPG Search:                                    | <input type="checkbox"/> Major revision                           |
|  |  | <input type="checkbox"/> The same title        |   |
|  |  | <input type="checkbox"/> Duplicate publication |   |
|  |  | <input type="checkbox"/> Plagiarism            |   |
|  |  | <input type="checkbox"/> No                    |   |

## COMMENTS TO AUTHORS

The Observational Study is well written, comprehensive and up-to-date. I think that it will be useful to a broad readership interested in an update on the most recent therapeutic strategies concerning control of prostatitis. I suggest publication of this review without modifications.

**Response:** We thank the reviewer for the encouraging comments.